.jpeg)
{{ variable.name }}
Tivozanib is a tyrosine kinase inhibitor that mainly acts on vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3.
Tivozanib is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more systemic therapies. It blocks tumor angiogenesis by inhibiting targets such as vascular endothelial growth factor receptor (VEGFR), thereby inhibiting tumor growth.
1.34mg is taken orally daily (either on an empty stomach or after meals), and the drug is taken continuously for 21 days and then stopped for 7 days (28 days is a cycle) until the disease progresses or intolerable toxicity occurs.
Adverse reaction management : Depending on the severity of adverse reactions, the dosage needs to be interrupted or reduced to 0.89 mg/day (21 days of medication + 7 days of discontinuation).
Hepatic insufficiency : Patients with moderate liver damage need to reduce the dose to 0.89mg/day; patients with severe liver damage should avoid use.
Attention when taking medicine : Swallow the capsule whole to avoid breakage. If you miss a dose, take the medicine at the originally planned time next time and do not take a double dose.
Common adverse reactions (≥20%) include fatigue, hypertension, diarrhea, decreased appetite, nausea, hoarseness, hypothyroidism, cough, and stomatitis. Be wary of serious side effects:
Cardiovascular risks : hypertensive crisis, heart failure, arterial/venous thrombosis (such as myocardial infarction, stroke).
Bleeding events : may be serious or even fatal, such as gastrointestinal bleeding and cerebral hemorrhage.
Other : Proteinuria, delayed wound healing, reversible posterior encephalopathy syndrome (RPLS), thyroid dysfunction.
Allergic reaction : The 0.89mg capsule contains tartrazine (FD&CYellowNo.5), which may cause asthma or allergic reactions.
Monitor blood pressure, thyroid function, urine protein, and liver function regularly before and during medication.
Medicine needs to be suspended before and after surgery: Medication should be stopped for at least 24 days before elective surgery, and restarted after the wound is completely healed after surgery.
There are no absolute contraindications, but the 0.89mg specification is prohibited for those allergic to tartrazine.
Pregnant women : It may cause fetal malformation, so strict contraception is required until 1 month after stopping the drug.
Lactation : Breastfeeding is prohibited during treatment and within 1 month of stopping the drug.
Fertility effects : May reduce male and female fertility.
Avoid coadministration with strong CYP3A inducers (such as rifampicin), which may reduce the efficacy of tivozanib.
Overdose may lead to severe hypertension, which requires immediate discontinuation and symptomatic supportive treatment. There is no specific antidote.